AbbVie lifts profit forecast as immunology drugs continue to fuel growth

AbbVie raised its annual profit forecast after Q3 earnings beat estimates, driven by strong sales of immunology drugs Skyrizi ($5.78B) and Rinvoq ($2.71B). The company's neuroscience portfolio also contributed to growth. AbbVie expects adjusted profit of $13.95-$13.99 per share, up from prior guidance. The company has gained 27% YTD.

Original reporting
Published Oct 30, 2026, 11:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AbbVie lifts profit forecast as immunology drugs continue to fuel growth — source image
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest a stronger earnings trajectory, supporting a bullish stance on ABBV.

02

Market read

New profit forecast and revenue beat provide a fresh catalyst for ABBV, likely influencing healthcare sector sentiment.

03

What to watch

Potential headwinds from upcoming Humira patent expirations and competition in the immunology space.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

AbbVie reported Q3 earnings beating estimates, with Skyrizi and Rinvoq driving growth as Humira loses exclusivity.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie raised its annual adjusted profit forecast to $13.95‑$13.99 per share after a Q3 earnings beat and strong immunology drug sales.

Expected impact

upward pressure as the market prices in the higher profit guidance.

Evidence & confidence

The new profit range exceeds prior expectations and follows a revenue beat, providing a clear catalyst for buying.

Market effects

Strengthens outlook for the broader biotech and pharma sector, especially companies with immunology pipelines.

Positive for US healthcare equities, may boost Nasdaq health‑care index.

Limited to investors tracking large‑cap US pharma; no immediate global macro effect.

Counterpoint

If the guidance upgrade is already priced in, the stock may face a short‑term pullback.

Key entities

  • AbbVie

    US‑listed biopharma company (ticker ABBV).

Related articles

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.

$ABBVHighAI 9/10

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

AbbVie will pay up to $2.54 billion to develop cancer treatments with private German biotech Disco Pharmaceuticals, including a $40 million upfront fee and milestone payments. Disco will handle research, with AbbVie having exclusive licensing rights. The deal focuses on AND-gated bispecific therapeutics for solid tumors, with Disco aiming to select a candidate in late 2024.